320 related articles for article (PubMed ID: 15736142)
1. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra.
Claxton K; Sculpher M; McCabe C; Briggs A; Akehurst R; Buxton M; Brazier J; O'Hagan T
Health Econ; 2005 Apr; 14(4):339-47. PubMed ID: 15736142
[TBL] [Abstract][Full Text] [Related]
2. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach.
Williams I; Bryan S; McIver S
J Health Serv Res Policy; 2007 Apr; 12(2):73-9. PubMed ID: 17407655
[TBL] [Abstract][Full Text] [Related]
3. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
4. NICE's use of cost effectiveness as an exemplar of a deliberative process.
Culyer AJ
Health Econ Policy Law; 2006 Jul; 1(Pt 3):299-318. PubMed ID: 18634698
[TBL] [Abstract][Full Text] [Related]
5. [Procedures and methods of benefit assessments for medicines in Germany].
Bekkering GE; Kleijnen J
Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
[TBL] [Abstract][Full Text] [Related]
6. Sensitivity analysis in economic evaluation: an audit of NICE current practice and a review of its use and value in decision-making.
Andronis L; Barton P; Bryan S
Health Technol Assess; 2009 Jun; 13(29):iii, ix-xi, 1-61. PubMed ID: 19500484
[TBL] [Abstract][Full Text] [Related]
7. Reallocating resources: how should the National Institute for Health and Clinical Excellence guide disinvestment efforts in the National Health Service?
Pearson S; Littlejohns P
J Health Serv Res Policy; 2007 Jul; 12(3):160-5. PubMed ID: 17716419
[TBL] [Abstract][Full Text] [Related]
8. The use of cost-effectiveness by the National Institute for Health and Clinical Excellence (NICE): no(t yet an) exemplar of a deliberative process.
Schlander M
J Med Ethics; 2008 Jul; 34(7):534-9. PubMed ID: 18591289
[TBL] [Abstract][Full Text] [Related]
9. Uncertainty in cost-effectiveness analysis. Probabilistic uncertainty analysis and stochastic league tables.
Baltussen RM; Hutubessy RC; Evans DB; Murray CJ
Int J Technol Assess Health Care; 2002; 18(1):112-9. PubMed ID: 11987434
[TBL] [Abstract][Full Text] [Related]
10. [More care for a limited budget; a case for a better use of the efficiency criteria].
Rutten FF; Brouwer WB
Ned Tijdschr Geneeskd; 2002 Nov; 146(47):2254-8. PubMed ID: 12481524
[TBL] [Abstract][Full Text] [Related]
11. Regarding probabilistic analysis and computationally expensive models: necessary and required?
Caro JJ; Getsios D; Möller J
Value Health; 2007; 10(4):317-8; author reply 319. PubMed ID: 17645686
[No Abstract] [Full Text] [Related]
12. Patients' views of explicit rationing: what are the implications for health service decision-making?
Devlin N; Appleby J; Parkin D
J Health Serv Res Policy; 2003 Jul; 8(3):183-6. PubMed ID: 12869346
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis and formulary decision making in England: findings from research.
Williams IP; Bryan S
Soc Sci Med; 2007 Nov; 65(10):2116-29. PubMed ID: 17698271
[TBL] [Abstract][Full Text] [Related]
14. Handling uncertainty of the economic evaluation result: sensitivity analysis.
Limwattananon S
J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S59-65. PubMed ID: 19253488
[TBL] [Abstract][Full Text] [Related]
15. Sensitivity analysis for handling uncertainty in an economic evaluation.
Limwattananon S
J Med Assoc Thai; 2014 May; 97 Suppl 5():S59-64. PubMed ID: 24964700
[TBL] [Abstract][Full Text] [Related]
16. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
Griebsch I; Coast J; Brown J
Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
[TBL] [Abstract][Full Text] [Related]
17. Has NICE been nice to cancer?
Summerhayes M; Catchpole P
Eur J Cancer; 2006 Nov; 42(17):2881-6. PubMed ID: 17070032
[TBL] [Abstract][Full Text] [Related]
18. Bridging the gap between methods research and the needs of policy makers: a review of the research priorities of the National Institute for Health and Clinical Excellence.
Longworth L; Sculpher MJ; Bojke L; Tosh JC
Int J Technol Assess Health Care; 2011 Apr; 27(2):180-7. PubMed ID: 21447260
[TBL] [Abstract][Full Text] [Related]
19. Decision making by NICE: examining the influences of evidence, process and context.
Cerri KH; Knapp M; Fernández JL
Health Econ Policy Law; 2014 Apr; 9(2):119-41. PubMed ID: 23688554
[TBL] [Abstract][Full Text] [Related]
20. From cost-effectiveness information to decision-making on liquid-based cytology: Mind the gap.
Legood R; Wolstenholme J; Gray A
Health Policy; 2009 Feb; 89(2):193-200. PubMed ID: 18619702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
